Status:
COMPLETED
Gene Expression Profiling of Breast Cancer Cells Predict the Response of Malignant Pleural Effusion
Lead Sponsor:
Peking University Cancer Hospital & Institute
Conditions:
Breast Neoplasms
Neoplasm Metastasis
Eligibility:
FEMALE
18-75 years
Brief Summary
The investigators want to develop a gene expression profile for the prediction of immunotherapy response of patients with metastatic breast cancer presenting malignant pleural effusion.
Detailed Description
1. The patiets with malignant pleural effusion are randomizned to be treated with cytokins(inteleukin 2) or dendritic cells(DC) plus cytokine induced killer cells(CIK) locally. 2. Malignant pleural ef...
Eligibility Criteria
Inclusion
- Patients should be histologically confirmed with metastatic breast cancer and malignant pleural effusion
- an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
- At least one measurable lesion;
- Normal cardiac, hepatic, renal and bone marrow functions;
- Life expectancy ≥3 months;
- Discontinuity of previous chemotherapy for a minimum of 4 weeks.
- Not receive chemotherapy in pleural cavity
Exclusion
- previous history of other malignancies;
- previous surgery history on the needle biopsy organ;
- Serious or uncontrolled concurrent medical illness.
Key Trial Info
Start Date :
November 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT01256801
Start Date
November 1 2010
End Date
December 1 2013
Last Update
July 29 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Cancer Hospital
Beijing, China, 100142